A population-based study comparing outcomes for patients with metastatic castrate resistant prostate cancer treated by urologists or medical oncologists with first line abiraterone acetate or enzalutamide
Woon DTS, Finelli A, Cheung DC, Martin LJ, Alibhai S, Wallis CJD, Diong C, Saskin R, Kulkarni G, Fleshner N. Urology. 2021; 153:147-55. Epub 2021 Feb 13.